Fibrin glue pleurodesis for pneumothorax in extremely preterm infants: A case report and literature review by Drovandi, Livia et al.
Drovandi et al. Italian Journal of Pediatrics  (2018) 44:91 
https://doi.org/10.1186/s13052-018-0533-6CASE REPORT Open AccessFibrin glue pleurodesis for pneumothorax
in extremely preterm infants: a case report
and literature review
Livia Drovandi1, Ilaria Cianchi1, Simone Pratesi1 and Carlo Dani1,2*Abstract
Background: Chest tube drainage and mechanical ventilation are effective treatment of symptomatic pneumothorax
(PTX), but the best management of persistent (> 7 days) PTX is unknown.
Case presentation: We reported a case of successful fibrin glue pleurodesis of persistent PTX in an extremely preterm
infant without adverse effects. We discussed previous literature on this treatment.
Conclusions: Overall, the twelve reported cases suggest that persistent PTX sealing with fibrin glue can represent a
simple, quick, and effective treatment whose possible reported adverse effects are transient and do not cause
permanent sequelae. Thus, fibrin glue pleurodesis might be considered a suitable therapeutic tool in very preterm
infant with persistent PTX.
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Pneumothorax (PTX) is one of the major complications
in extremely preterm infants with respiratory failure and
is associated to high mortality and morbidity [1, 2]. After
the introduction of surfactant replacement therapy, its
incidence is dropped and now is around 1–2% [1, 2].
Asymptomatic PTX without underlying pulmonary disease
does not require any treatment, but in case of symptomatic
PTX insertion of a chest tube and air drainage are required
[1]. Although necessary, chest tube placement can lead to
several complications in neonates, such as lung injuries, in-
sertion site and pulmonary infections, phrenic nerve par-
alysis, chylothorax, and hemorrhagic pericardial effusion
[1]. Usually chest tube drainage, positioning with the af-
fected side down, low lung volume strategy, and high fre-
quency oscillatory ventilation are effective treatment of
PTX and allow its recovery in few days but, sometimes,
mainly in patients with large bronchopleural fistulas, it can
persist for several days [2].* Correspondence: cdani@unifi.it
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7 days should be defined as persistent PTX [3]. They
demonstrated that preterm infants with persistent PTX
have higher risk of developing chronic lung disease than
infants in whom PTX resolved before [3].
Unfortunately, there are not guidelines indicating the
most appropriate approach to persistent PTX before
considering more invasive procedures, such as pleurect-
omy, chemical pleurodesis, and selective intubation of the
contralateral bronchus [4]. On the other hand, the risk of
associated morbidities, such as intracranial hemorrhage,
acute hypotension, air embolus and circulatory failure,
urges the treatment of persistent PTX [2].
Fibrin glue is a two-component material consisting of
concentrated human fibrinogen and thrombin imitating
the coagulation process of the body. By combining the
thrombin and fibrinogen component conversion of fi-
brinogen to fibrin takes place and a clot is formed by a
three-dimensional fibrin network [5]. Fibrin glue on-label
indications in adults include hemostasis, colonic sealing,
and skin graft attachment [6]. Recent clinical and experi-
mental uses include tissue or mesh attachment, fistula
closure, lymphatic sealing, adhesion prevention, drug de-
livery, and tissue engineering [6].le is distributed under the terms of the Creative Commons Attribution 4.0
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ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Fig. 1 PTX in the first and fourteenth day of life. Chest x-ray showing right-sided PTX in the first day of life (a) persisting in the fourteenth day
of life (b)
Fig. 2 Chest x-ray after fibrin glue injection. Chest x-ray at 30 min (a) and 12 h (b) after fibrin glue injection. A minimal PTX was appreciable in
(a) and disappeared in (b). At the distal tip of the chest tube is visible a radiopaque area referable to the fibrin glue clot more evident in (b)
than in (a)
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Fig. 3 Chest x-ray at discharge. Chest x-ray at 78 day of life showing
the disappearance of the fibrin glue
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seal a persistent PTX in a preterm infant has been re-
ported in 1993 by Berger et al. [7]. From then, other case
reports have been published [1, 2, 8, 9] suggesting that
this procedure is effective in sealing persistent PTX in
these patients without inducing severe adverse effects.
Thus, the purpose of this report is to document a fur-
ther case of fibrin glue pleurodesis of persistent PTX in
an extremely preterm infant, and to discuss previous lit-
erature on this issue for drawing the attention of Neona-
tologists to this little-known promising treatment.
Case presentation
A male was born at 26 weeks of gestation by cesarean sec-
tion due to maternal vaginal bleeding after antenatal ste-
roids. His birth weight was 810 g and Apgar scores were 7
at 1 min and 8 at 5 min. Non-invasive mechanical ventila-
tion (N-IMV with the following parameters: peak inspira-
tory pressure 18 cm H2O, respiratory rate 60/min, positive
end expiratory pressure 5 cm H2O, FiO2 0.35) was started
immediately after delivery because of respiratory distress
and continued in neonatal intensive care unit (NICU).
Our patient was treated with surfactant (200 mg/kg of
Curosurf, Chiesi Farmaceutici Spa, Parma, Italy) with the
InSURE (Intubation-SURfactant-Extubation) procedure at
2 h of life when FiO2 was 0.40. At 24 h of life a second
dose of surfactant (100 mg/kg) was given (again with the
InSURE procedure) for the worsening of respiratory fail-
ure (FiO2 0.45), but immediately after the procedure he
developed a right-sided PTX (Fig. 1). Therefore, high fre-
quency oscillatory ventilation (HFOV) was started and
chest tube was placed on 10 cm H2O suction for continu-
ous pleural drainage. On the fourteenth day of life the
PTX persisted (Fig. 1) and, obtained informed parental
consent, we performed chest pleurodesis with fibrin glue.
The homologous fibrin glue (Tisseel®, Baxter, Lurago
d’Erba, Italy) was prepared in a prefilled double chamber
syringe which contains sealer protein solution (with syn-
thetic aprotinin) in one chamber and thrombin solution
(with calcium chloride) in the other chamber resulting in
10 ml of product ready for use. The administration pro-
cedure was similar to previous reports [1, 2, 7–9]: a 5-Fr
umbilical catheter was placed into the 10F chest tube dur-
ing HFOV and 5 mL of fibrin were slowly injected into
the right pleural space. After the tube was completely
pulled by the glue, the catheter was slowly extracted. Dur-
ing the 5 min injection heart rate was stable, and SpO2
was > 90% with unchanged FiO2. The procedure was
followed by a quick and marked reduction in airflow
through the chest tube and chest X-ray performed 30 min
later showed a minimal right PTX (Fig. 2). After 12 h, no
air outflow was visible through the chest tube and PTX
disappeared at chest X-ray (Fig. 2); 24 h later the tube was
clamped and 48 h after the fibrin glue pleurodesis it wasdefinitely removed. Five days later mechanical ventilation
was stopped, and non-invasive ventilatory support was fi-
nally interrupted on 78 day of life when chest X-ray dem-
onstrated the disappearance of fibrin glue clot (Fig. 3).
Discussion
The management of persistent PTX is not well estab-
lished but prolonged chest tube placement and mechan-
ical ventilation certainly increase the risk of developing
severe complications (i.e.: infections, hemodynamic dis-
turbances, bronchopulmonary dysplasia, etc.), especially
in the subset of preterm infant population. Therefore, a
relatively simple and quick procedure such as the fibrin
glue pleurodesis may be very appealing for the treatment
of persistent PTX.
Previous studies reported eleven cases of persistent PTX
sealing with fibrin glue in very preterm infants [1, 2, 7–9]
(Table 1). As in our case, fibrin glue pleurodesis was suc-
cessful in all survived patients in whom PTX resolved
within 48 h from the treatment as demonstrated by con-
trol chest x-rays [1, 2, 7–9]. The dose of fibrin glue varied
from 3.5 [2] to 10 mL [7], in relationship to different
Table 1 Summary of reported cases of fibrin glue pleurodesis for persistent PTX in preterm infants
Gestational age (wks) Birth weight (g) Number of cases Age at treatment (d) Fibrin glue dose (mL) Complications
Berger [7] 26 850 1 30 10 –
Kuint [9] 31 – 1 59 5 –
Sarkar [8] 24–29 530–1500 7 Bradycardia, hypercalcemia,
skin necrosis, transient
diaphragm paralysis
Campolat [2] 25 790 1 15 3.5 –
Nishizaki [1] 25 764 1 8 6 –
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the majority of cases a single course of fibrin glue was
effective [1, 2, 7–9], but in two cases of recurrent PTX
a second course was successfully performed [8]. More-
over, one patient had bilateral persistent PTX and re-
ceived successful bilateral treatment [1]. Adverse effects
were associated to the procedure in 5 patients in a sin-
gle study [8], including bradycardia, hypercalcemia, skin
necrosis, and diaphragmatic paralysis. It has been spec-
ulated that most of the complications (bradycardia, hy-
percalcemia, and the skin necrosis) were secondary to
the concentration of calcium in the fibrin glue [8].
Nevertheless, these adverse effects did not occur in the
remaining 7 patients (including ours) [1, 2, 7], and, in
any case, they were transient and did not cause severe
permanent sequelae [1, 2, 7–9]. However, the actual
role of calcium is difficult to evaluate because different
types of fibrin glue with different calcium content were
used [1, 2, 7–9]. Possible effects of fibrin glue on pa-
tients’ long-term pulmonary function might be a source
of concern, However, our case and previous studies
showed that chest X-rays performed at discharge [7], or
later [1, 9] did not evidence lung abnormalities refer-
able to fibrin glue pleurodesis.
Between possible treatments of persistent PTX, pleur-
ectomy is too much invasive and, therefore, unfeasible in
very preterm infants, while selective intubation of contra-
lateral bronchus is very difficult particularly when the left
main stem bronchus has to be selectively intubated. Pleur-
odesis with povidone-iodine has been reported in refrac-
tory chylotorax in newborns [10] and in a single-case of
persistent PTX [4]. However, the use of povidone-iodine
for pleurodesis can rise some concerns in very preterm in-
fants due its chemical inflammatory effects, and the
iodine oxidative and cytotoxic properties plus the risk
of secondary hypothyroidisms [4, 10]. Moreover, the
povidone-iodine pleurodesis in neonates has been asso-
ciated with adverse effects, such as pain [11], lung or
lobar collapse [11], and acute renal failure [12]. Con-
versely, fibrin glue is a human product that is catabo-
lized by physiologic fibrinolytic agents whose reported
adverse effects seem to be less severe.Conclusions
The best management of persistent PTX in very preterm
infants has not been reported in literature and the ap-
propriate duration of standard therapy (pleural drainage
through a chest tube during mechanical ventilation) be-
fore considering more invasive procedures has not been
established. We reported a case of persistent PTX in an
extremely low birth-weight infant who was successfully
treated with fibrin glue pleurodesis. Our and previous
case reports [1, 2, 7–9] suggest that persistent PTX
sealing with fibrin glue can represent a simple, quick,
and effective treatment whose possible reported adverse
effects are transient and do not cause permanent se-
quelae. Thus, we believe that fibrin glue pleurodesis
might be considered a suitable therapeutic tool in very
preterm infant with persistent PTX.
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